Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Knight Therapeutics Inc T.GUD

Alternate Symbol(s):  KHTRF

Knight Therapeutics Inc. is a Canada-based specialty pharmaceutical company. The Company's principal business activity includes developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invested in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The Company's portfolio consists of pharmaceutical products with molecules and includes both in-licensed products, such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome as well as products owned (or partially owned) by it, such as Exelon and Impavido.


TSX:GUD - Post by User

Comment by MrMugsyon Jul 12, 2022 9:13am
188 Views
Post# 34817512

RE:New NCIB in place on the 14th

RE:New NCIB in place on the 14th
EbbFlow88 wrote: So, as of June 30th we now have 114.6M shares outstanding. 79.9M of which are public float. On thursday, we can now buy up to 7.99M shares. 

As Mugsy has mentioned before as well as a few others, the float is getting tighter and tighter as savvy allocators are picking up cheap shares. Just a matter of time.


Exactly !

-------------------------

"Groundhog Day" as it pertains to the way Goodman/Samira operate.  They are very consistent.

-------------------------

Sure we'd all like to get-rich-quick ... but ...

I prefer the ones that I understand from the get-go.
The one's I don't have to worry about ... when to get in/when to get out.

It's not exciting - but it's how you build a pharma licensing company and how you accumulate wealth over time (IMO).

<< Previous
Bullboard Posts
Next >>